Medication for reducing alcohol use in people with fatty liver and obesity
Treatments studied
Part of Digestive system, Hormones & metabolism, Mental health clinical trials.
This study tests whether a weekly injection (a GLP-1 medication similar to semaglutide) can help people with obesity and fatty liver reduce their alcohol intake and improve liver health. It may be an option if you drink more than moderate amounts and have fatty liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a body mass index (BMI) of 35 or higher, or 28 or higher if you also have diabetes, pre-diabetes, high blood pressure, or abnormal cholesterol.
- You must have fatty liver disease, confirmed by an ultrasound or a special scan.
- You must be between 18 and 80 years old.
- You must have a certain level of alcohol consumption, as measured by a quick questionnaire (score of 4+ for women, 5+ for men).
- You must be able to speak and understand German or French.
- You cannot be taking certain medications for alcohol dependence, have active illicit substance use, or have had cancer in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a weekly medicine called semaglutide can help veterans who drink heavily reduce their alcohol intake. If you're a veteran and want to cut down on drinking, this study may be an option.
This study tests if a medication called semaglutide (used for diabetes and weight loss) can help reduce alcohol craving and drinking. It also looks at how the drug affects stress hormones and metabolism, which may help you drink less and lose weight.
This study is testing whether semaglutide, a medication already used for diabetes and weight loss, can help people with HIV who also have an alcohol use disorder cut back on drinking. It is for patients treated at the Atlanta VA Healthcare System.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Hear when a new Adiposity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.